KAT7 (lysine acetyltransferase 7) is also known as histone acetyltransferase binding to ORC1 (HBO1)/ MYST2 (histone acetyltransferase). It is an oncoprotein and the catalytic subunit of the main histone H4 acetyltransferase complex in human 293T cells. KAT7 is located on human chromosome 17q21.
Synonyms: Anti-HBO1; Anti-HBOA; Anti-MYST2; Anti-ZC2HC7
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: KAT7 (lysine acetyltransferase 7) induces the multiplication of cells in bladder cancer by activating Wnt/ß-catenin signalling. It is essential for DNA replication. KAT7 modulates CENP-A (histone H3-like centromeric protein A) chromatin assembly. It also stimulates histone exchange/turnover.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC